-+ 0.00%
-+ 0.00%
-+ 0.00%

Assembly Bio highlights Phase 2 starts for ABI-6250, GS-1179 in pipeline update

PUBT·09/08/2026 20:08:46
Listen to the news
Assembly Bio highlights Phase 2 starts for ABI-6250, GS-1179 in pipeline update
  • Assembly Biosciences outlined multiple Phase 2 starts across its portfolio in 2026 to early 2027, led by ABI-6250 in liver diseases.
  • ABI-6250 Phase 2 in hepatitis D expected in 4Q 2026, with data expected in 4Q 2027; PBC/PSC Phase 2 expected 1Q 2027.
  • Gilead-selected HSV candidate GS-1179 targets Phase 2 initiation in recurrent genital herpes in 4Q 2026.
  • Cash runway projected into 2029, supported by a $320.4 million cash position at June 30, 2026.
  • Gilead collaboration extension payment of $75 million due in 4Q 2026, with additional $75 million payments due in 2028 and 2030.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Assembly Biosciences Inc. published the original content used to generate this news brief on September 04, 2026, and is solely responsible for the information contained therein.